Valbiotis Preps for TOTUM•63 Launch After Nestlé Split

Valbiotis SA (FR:ALVAL) has released an update.

Valbiotis SA regains full control over TOTUM•63, a plant-based dietary supplement for prediabetes and early type 2 diabetes management, after terminating its agreement with Nestlé Health Science. With the recapture of all related intellectual property and a strong cash position of €25 million, Valbiotis is preparing for the direct launch of TOTUM•63 in France by H1 2025 and seeks new international partnerships.

For further insights into FR:ALVAL stock, check out TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.